Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GLSI, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| HER2/neu Peptide Vaccine GLSI-100 | Breast Cancer | Phase 3 · NCT05232916 | Recruiting |
Also used in these trials (approved or third-party drugs, not GLSI's own candidates): Carboplatin, Cetuximab, Paclitaxel.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GLSI holds $5.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 7.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GLSI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Snehal Patel CEO and CFO, Director, 10% owner · +4.59M options |
Insider | 5,611,402 | 38.23% | 2026-07-28 |
| Blackrock Inc. | Institution (13F) | 511,991 | 3.49% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 288,610 | 1.97% | 2026-09-30 |
| Jaye Thompson VP Clinical Reg Affairs · +299,636 options |
Insider | 264,148 | 1.80% | 2024-11-21 |
| Geode Capital Management, LLC | Institution (13F) | 187,239 | 1.28% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 159,448 | 1.09% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 92,885 | 0.63% | 2026-09-30 |
| Northern Trust Corporation | Institution (13F) | 82,754 | 0.56% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 56,793 | 0.39% | 2026-09-30 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 53,226 | 0.36% | 2026-09-30 |
| Bank Of New York Mellon Corporation | Institution (13F) | 48,999 | 0.33% | 2026-09-30 |
| STRS Ohio | Institution (13F) | 34,700 | 0.24% | 2026-09-30 |
Share count 14,678,208 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-29 filed 2026-07-30 |
Patel Snehal |
Purchase (P) | 700 | $13.10 | 5,611,402 |
| 2026-07-28 filed 2026-07-30 |
Patel Snehal |
Purchase (P) | 1,500 | $13.59 | 5,610,702 |
| 2026-07-27 filed 2026-07-29 |
Patel Snehal |
Purchase (P) | 1,500 | $13.62 | 5,609,202 |
| 2026-07-24 filed 2026-07-27 |
Patel Snehal |
Purchase (P) | 1,100 | $12.88 | 5,607,702 |
| 2026-07-23 filed 2026-07-27 |
Patel Snehal |
Purchase (P) | 2,500 | $13.14 | 5,606,602 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GLSI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →